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hearing loss. To date, a myriad of adeno-associated virus
(AAV) serotypes and surgical approaches have been employed
to deliver transgenes to cochlear hair cells, but the efficacy of
dual transduction remains unclear. Herein, we investigated
cellular tropism of single injections of AAV serotype 1
(AAV1), AAV2, AAV8, AAV9, and Anc80L65, and quanti-
tated dual-vector co-transduction rates following co-injection
of AAV2 and AAV9 vectors in adult murine cochlea. We used
the combined round window membrane and canal fenestra-
tion (RWM+CF) injection technique for vector delivery. Sin-
gle AAV2 injections were most robust and transduced
96.7% ± 1.1% of inner hair cells (IHCs) and 83.9% ± 2.0% of
outer hair cells (OHCs) throughout the cochlea without
causing hearing impairment or hair cell loss. Dual AAV2 in-
jection co-transduced 96.9% ± 1.7% of IHCs and 65.6% ±
8.95% of OHCs. Together, RWM+CF-injected single or dual
AAV2 provides the highest auditory hair cell transduction ef-
ficiency of the AAV serotypes we studied. These findings
broaden the application of cochlear gene therapy targeting
hair cells.
INTRODUCTION
In monogenic diseases, gene therapy can be employed to correct or
suppress a mutant gene, or to replace a wild-type gene, thereby
achieving successful habilitation.1 The delivery of the transgene to
the relevant target tissue is a key component to successful gene ther-
apy, with viral vectors commonly utilized for this purpose because
their transduction properties are superior to non-viral vectors.2
Among viral vectors, adeno-associated viruses (AAVs) have become
increasingly popular as a gene delivery vector for virus-based
gene therapies, with two AAV-based gene therapies currently
approved by the US Food and Drug Administration: LUXTURNA
(voretigene neparvovec-rzyl) for Leber’s congenital amaurosis
and ZOLGENSMA (onasemnogene abeparvovec-xioi) for spinal
muscular atrophy.Molecular Therapy: Methods & C
This is an open access article under the CC BY-NC-NThe characteristics of broad cellular tropism, non-ototoxicity, and
low immunogenicity have also attracted interest in utilizing AAVs
for inner ear therapeutic applications.3 Because approximately
two-thirds of all genes implicated in non-syndromic sensorineural
hearing loss are expressed in both inner hair cells (IHCs) and outer
hair cells (OHCs),4 gene delivery methods that target both cell types
are necessary to restore full auditory sensitivity.5 Currently, the
cellular tropism of 12 naturally occurring serotypes of human
AAVs and several other synthetic AAVs has been characterized.1
Studies have defined the in vivo transduction properties of these
AAV serotypes in neonatal and adult murine ear using various inoc-
ulation methods.6–10 In aggregate, these studies have demonstrated
that multiple factors, including age, vector serotype, promoter
type, injection method, and viral titers, impact cellular tropism
and transduction efficiency in the murine inner ear.1 Importantly,
several AAV serotypes, such as AAV 2/1 (AAV1), 2/2 (AAV2),
2/8 (AAV8), 2/9 (AAV9), and 2/Anc80L65 (Anc80), have been re-
ported to transduce IHCs consistently, although gene transfer to
the OHCs has been variable.5
Substantial efforts have also focused on developing an intracochlear
delivery method that permits broad and robust inner ear transduc-
tion. We recently described one such method that combines round
window membrane injection and canal fenestration (RWM+CF).4
This approach facilitates circulation of the vector throughout the
cochlea by creating a ventilation hole in the posterior semi-circular
canal. The result is broad distribution of the viral suspension in the
perilymph, thereby enhancing overall transduction. To date, however,linical Development Vol. 17 June 2020 ª 2020 The Author(s). 1167
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Transduction of IHCs and OHCs in Adult Mice Is Most Efficient with AAV2 Delivered Using the RWM+CF Injection Approach
(A) Cochleae harvested 2 weeks after administrating five AAV serotypes through RWM+CF in 4-week-old C3H/FeJ mice. Representative low-magnification images of whole-
mount apical turns and high-magnification images of regions along cochlea duct 0.8–1.2 mm (apex), 2.2–2.6 mm (middle), and 3.8–4.2 mm (base) from the apical tip.
(legend continued on next page)
Molecular Therapy: Methods & Clinical Development
1168 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020
www.moleculartherapy.orgthe inner ear transduction profile of hair cell-specific AAV subtypes
has not been fully explored with RWM+CF injection.1
AAVs have a small viral loading capacity: no more than 5.0 kb can be
inserted.11,12 This limitation is significant because the coding
sequence of many causative genes exceeds the loading capacity of a
single AAV.13,14 To circumvent this problem, researchers have adapt-
ed the dual-vector approach to enable delivery of larger trans-
genes.13,14 This method utilizes the intrinsic property of AAV to un-
dergo concatamerization when separate vectors co-transduce a single
cell. Importantly, efficient dual-vector co-transduction in the target
tissue is essential to achieve successful gene expression levels of these
large coding sequences. Although the co-transduction efficiency of
dual vectors in retina and neurons has been investigated, the dual-
vector co-transduction rate in the inner ear has not been analyzed
in adult mice.15
To identify AAV serotypes that transduce both mature murine IHCs
andOHCs, we first selected fiveAAV serotypes, AAV1, AAV2,AAV8,
AAV9, andAnc80, to inject into the cochlea using the RWM+CF tech-
nique. All vectors carried a CMV-driven EGFP transgene and the
woodchuck hepatitis post-transcriptional virus regulatory element
(WPRE) cassette. Viral suspensions were equal at 3.75–3.80  1012
genome copy (GC)/mL, allowing fair comparison and assessment of
the cellular tropism of eachAAV serotype.We then assessed dual-vec-
tor co-transduction efficiency in the cochlea following RWM+CF co-
injection of combinations of AAV2 or AAV9 vectors expressing either
EGFP or mCherry fluorescent protein.
Herein, we demonstrate that a single AAV2 injection transduces
96.7% ± 1.1% of IHCs and 83.9 ± 2.0% of OHCs (mean ± standard
error) in adult mice without causing hearing impairment or hair
cell (HC) loss. Dual-vector co-transduction with AAV2-EGFP and
AAV2-mCherry is comparable (IHC transduction, 96.9% ± 1.7%;
OHC transduction, 65.6% ± 9.0%). Thus, both single- and dual-
AAV2-mediated gene transfer delivered via the RWM+CF approach
enable efficient and specific HC transduction in a mature mouse
model. These findings expand the application of cochlear gene ther-
apy targeting mechanosensory hair cells in the inner ear.RESULTS
RWM+CF Injection with AAV2 Leads to High IHC and OHC
Transduction in All Cochlear Turns
To investigate the transduction profile of five AAV serotypes, we in-
jected the left ear in 4-week-old C3H/FeJ mice using the RWM+CF
technique. Two weeks later, both ears were harvested and quantitated
in whole-mount preparations. Quantification of IHC transduction
showed nearly total GFP localization in IHCs in all turns of the co-
chlea with both AAV2 (apex 92.8% ± 5.1%, middle 97.2% ± 3.2%,Cochleae were stained with Myo7a (red) for labeling and imaged for native EGFP (gree
transduction efficiency assessed in 400-mm segments across different regions of the
serotypes. Data are represented as mean ± SEM.
Moleculabase 100%; overall 96.7% ± 1.1%) and Anc80 (apex 100%, middle
99.5% ± 1.1%, base 99.2% ± 1.8%) (Figures 1A and 1B). AAV8 and
AAV9 also demonstrated robust transgene expression in IHCs
throughout the cochlea duct (AAV8: apex 64.9% ± 13.0%, middle
92.3% ± 3.9%, base 98.1% ± 2.7%; AAV9: apex 64.9% ± 13.0%, middle
92.3% ± 3.9%, base 98.1% ± 2.7%, respectively), whereas AAV1 trans-
duction of IHC was the least efficient among all serotypes (apex
12.8% ± 9.6%, middle 5.5% ± 2.0%, base 6.3% ± 6.8%). AAV2 demon-
strated the highest OHC transduction with an apex-to-base gradient
(apex 94.9% ± 3.5%, middle 86.5% ± 8.0%, base 69.4% ± 8.8%; overall
83.9% ± 2.0%). OHC transduction utilizing Anc80 was lower (apex
65.6% ± 23.6%, middle 27.4% ± 16.7%, base 36.1% ± 18.4%) (Figures
1A and 1C). GFP distribution in OHCs with AAV1, AAV8, and
AAV9 was poor in all turns (<5%). These observations indicate that
HC tropism is serotype specific, and that among five equally titrated
AAV serotypes, AAV2 has the highest total IHC and OHC transduc-
tion rate.AAV1, AAV2, AAV9, and Anc80 Do Not Change Auditory
Thresholds or Cause Degeneration of Hair Cells
We investigated auditory function by measuring auditory brainstem
response (ABR) thresholds 2 weeks after administration of each
AAV vector to assess potential functional ototoxicity. Both ears
were measured in all animals from each group, with the right ear
serving as a control. In four serotypes of AAVs (AAV1, AAV2,
AAV9, and Anc80), we observed no statistically significant differ-
ences in click and tone-burst ABRs across all frequencies between
ears. However, injection of AAV8 led to an elevated click-evoked
ABR threshold shift of 12 dB as compared with contralateral ears,
whereas tone-burst ABRs remained comparable between ears (Fig-
ure 2). These findings suggest that the injection of AAV serotypes
into the adult mouse cochlea does not alter auditory function, perhaps
with the exception of AAV8. In daily monitoring of the postoperative
health of the treated mice, we did observe transient circling behavior
immediately after surgery that resolved within 24 h. No other behav-
ioral side effects were noted (e.g., head tilting, weight loss, circling, or
ear infection). To investigate potential cellular ototoxicity of each
AAV serotype, we quantitated hair cell survival in RWM+CF-injected
and non-injected ears in whole-mount preparations along the entire
extent of the cochlear duct. Figure 3 indicates that IHC and OHC sur-
vival rates are comparable between injected and non-injected ears for
all serotypes, withmodest reductions for IHCs in the Anc80 condition
and OHCs in the AAV8 condition.Vestibular Organs Are Effectively Transduced following AAV8,
AAV9, and Anc80 Injection
Quantitative assessment of whole-mount preparations of vestibular
saccule epithelia revealed robust EGFP expression in vestibular HCs
following AAV8, AAV9, and Anc80 injection (30.0% ± 13.1%,n). Scale bar, 100 mm. (B and C) Quantitative comparison of IHC (B) and OHC (C)
cochlea (apex, middle, and base) following the RWM+CF injection of various AAV
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Figure 2. RWM+CF Injection Does Not Change ABR Thresholds in Adult Mice
Click and tone-burst ABRs show auditory thresholds in injected (solid lines) and non-injected (dashed lines) ears were comparable following delivery of AAV1, AAV2, AAV9,
and Anc80. Data are represented as mean ± SEM. Statistical analysis by Student’s t test. *p < 0.05.
Molecular Therapy: Methods & Clinical Development18.9% ± 1.3%, and 29.1% ± 10.4%, respectively) (Figure 4). We noted
a predilection for transduction of type II hair cells, which generally
constitute cells with nuclei closer to the endolymphatic side of the
epithelium as compared with type I hair cells (Figure 5), consistent
with observations when Anc80 is delivered by canalostomy injec-
tion.16 AAV2 did not demonstrate saccular HC transduction, which
is contrary to cochlear HC results, suggesting that AAV2 tropism is
cochlear hair cell specific. The AAV1 demonstrated GFP expression
in the non-sensory tissue of the vestibule.
Partial Transduction of the Stria Vascularis, Spiral Ganglion
Cells, Saccules, and Scarpa’s Ganglion Cells Is Observed
To define the non-sensory transduction profile of AAVswithin the or-
gan of Corti (i.e., supporting cells [SCs], stria vascularis [SV], spiral
ganglion cells, saccules, and Scarpa’s ganglion cells), we analyzed
cochlear and vestibular frozen cross sections in injected mice (Fig-
ure 5). EGFP transgene expression was detected in the SV in all
AAV serotypes with the exception of AAV2. Vectors AAV8, AAV9,
andAnc80 showed some degree of EGFP signal in spiral ganglion cells
and Scarpa’s ganglion cells.We did not detect EGFP expression in SCs
of the organ of Corti, including pillar cells and interphalangeal cells.
Co-transductionwithDual AAV2Demonstrates Comparable IHC
and OHC Transduction Rates to Single AAV2
The following combinations of dual vectors were injected into the left
ear in 4-week-old mice using the RWM+CF technique: AAV2-EGFP
and AAV2-mCherry (hereafter noted as AAV2-2), AAV2-EGFP and1170 Molecular Therapy: Methods & Clinical Development Vol. 17 JuneAAV9-mCherry (AAV2-9), and AAV9-EGFP and AAV9-mCherry
(AAV9-9). For each pair, we evaluated the co-transduction ratio;
i.e., the ratio at which both vectors transduced the same cell. For com-
parison, we performed single-vector injection with AAV2-EGFP,
AAV2-mCherry, AAV9-EGFP, and AAV9-mCherry.
With AAV2-2, we observed robust co-transduction of IHCs and
OHCs (IHCs: apex 94.6% ± 4.7%, middle 98.1% ± 1.9%, base
98.1% ± 1.5%; OHCs: apex 93.0% ± 4.4%, middle 80.0% ± 9.6%,
base 23.8% ± 12.9%) that was identical to that observed with either
vector alone (AAV2-2 versus AAV2-EGFP in IHCs and OHCs: p >
0.9999 and p > 0.9999, respectively; AAV2-2 versus AAV2-mCherry
in IHCs and OHCs: p > 0.9999 and p > 0.9999, respectively). IHC and
OHC survival rates were comparable between injected and non-in-
jected ears (Figure S1). Likewise, the co-transduction rates of
AAV2-9 and transduction rate of AAV2-EGFP for IHCs were similar
(AAV2-9 versus AAV2-EGFP in IHCs: apex p > 0.9999, middle p >
0.9999, base p > 0.9999). However, AAV2-9 co-transduction rates
were significantly higher than AAV2-EGFP transduction rates for
OHCs in the basal turn of the cochlea (AAV2-9 versus AAV2-
EGFP in OHCs: apex p = 0.0052, middle p = 0.0008, base p >
0.9999) (Figure S2B). AAV2-9 and AAV9-mCherry transduction
rates for IHCs and OHCs were comparable (AAV2-9 versus
AAV9-mCherry in IHCs and OHCs: p > 0.9999 and p > 0.9999,
respectively; AAV2-9 versus AAV9-mCherry in IHCs and OHCs, p
> 0.9999 and p > 0.9999, respectively). Finally, with AAV9-9, trans-
duction rates were significantly lower as compared with transduction2020
Figure 3. Quantitative Comparison of IHC and OHC
Survival in Injected and Non-injected Ears Reveals
that AAV8 and Anc80 Delivery Results in Hair Cell
Loss
Hair cell counting in 400-mm segments across different
regions of the cochlea (apex, middle, and base) as docu-
mented 2 weeks post-injection. Data are represented as
mean ± SEM. Statisticalanalysis by one-way ANOVA.
***p < 0.001; **p < 0.01.
www.moleculartherapy.orgwith AAV9-EGFP alone (AAV9-9 versus AAV9-EGFP: apex p =
0.0026, middle p < 0.0001, base p = 0.0003). Interestingly, IHC trans-
duction of AAV9-mCherry in the base was higher with dual transduc-
tion than with single transduction (p = 0.0152) (Figure S2). All com-
binations had no hair cell loss (Figure S1).
DISCUSSION
Themajority of genetic non-syndromic hearing loss is associated with
genes expressed in the IHCs and/or OHCs, making the development
of gene delivery vectors and injection methods that facilitate trans-
duction of these cell types essential to gene therapy-based strategies
to treat hearing loss.4,5 We demonstrate that among five AAV sero-
types tested (AAV1, AAV2, AAV8, AAV9, and Anc80) using a
RWM+CF approach, transgene expression is most robust with
AAV2 in both IHCs (97%) and OHCs (84%). Using dual vectors,
we demonstrate that AAV2-2 co-transduction efficiency of hair cells
is comparable with that observed with AAV2 alone. Auditory func-
tion and hair cell survival in injected versus non-injected ears are
similar whether single- or dual-vector injections are performed, mak-
ing AAV2 an excellent candidate vector for single and/or dual appli-
cations that require hair cell transduction.
Although AAV2 is the most commonly studied AAV serotype in the
central nervous system (CNS), its utility in cochlear gene therapy
studies has been limited, partially because of its poor tropism for
hair cells in neonatal mouse cochlea.6,7,10 For instance, when
AAV1, AAV2, AAV8, and Anc80 are delivered to neonatal mouse co-
chlea through the RWM, EGFP transduction in IHCs and OHCs is
poorest with AAV2.7 In a recent study in the adult mouse cochlea
in which AAV2 harboring GFP was delivered via canalostomy, how-
ever, near-total IHC transduction was observed, althoughOHC trans-
duction was only partial (12.1% in the apex, 7.1% in the middle, and
1.6% in the base), despite using a 3-fold higher AAV2 titer than we
used in this study (1  1013 versus 3.68  1012 GC/mL).8 These dif-
ferences in transduction efficiency and cell tropism suggest that ani-
mal age, strain, and method of delivery remain important determi-
nants of outcome. Viral titer, viral purifying and processing
differences, and the presence of WPRE also can impact GFP expres-
sion.4,17 Interestingly, we found that AAV2 does not transduce vestib-
ular hair cells despite robust transduction in cochlear hair cells, sug-
gesting that AAV2 tropism is more specific than that of other AAVs.Molecular Therapy: Methods &New synthetic vectors such as Anc80 have
emerged as an alternative to conventional AAVvectors, and transduce IHCs and OHCs with high efficiency when in-
jected through either perilymph or endolymph in both neonatal and
adultmice.4,5,7,8,16,18Consistentwith previous reports,we demonstrated
thatAnc80 viaRWM+CF injection in adultmice transducedvirtually all
IHCs.8,16 Like others, we noted an apex-to-base gradient (apex 65.6%±
23.6%, middle 27.4% ± 16.7%, base 36.1% ± 18.4%) in OHC transduc-
tion; however, our data demonstrated superior GFP transduction in the
basal turn (36% versus 10%) when comparable viral titers are used,8,16
suggesting that the RWM+CF technique may increase inner ear trans-
duction efficiency. Irrespective of the AAV serotype we used, localiza-
tion of EGFP signals in SCs was not achieved using the RWM+CF
approach, a disappointing result that likely precludes the use of these
AAVs for GJB2-focused gene therapy programs. Viral vectors such as
AAV-inner ear, AAV2.7m8, bovine AAV, and adenovirus may be
more suitable for selective SC transduction.9,19–21
It remains unclear why our results appear to diverge from those in
prior studies, particularly the observed transduction rates of AAV1
and Anc80 for IHCs and OHCs, respectively, as compared with
AAV2. By design, our study leverages a route of administration
that differs from routes used in other studies assessing AAV trans-
duction in the cochlea. Dose, titer, and transgene design can also
lead to distinct differences in IHC and OHC transduction efficiency
for a given viral vector. Lastly, not to be underestimated is the
impact of genetic background. Our studies in C3H/FeJ mice may
illustrate the dependency of route of administration, mouse strain,
and age on the efficiency and tropism of AAV subtypes
compared with prior studies in CBA/CaJ16 and C57BL/6,7,8 similar
to observations with AAV-PHP.B in CNS targeting via systemic
administration.22,23
In the vestibule, AAV8, AAV9, and Anc80 gave robust EGFP sig-
nals in the saccule, suggesting potential for these vectors with ther-
apies designed to target both auditory and balance disorders. We
also demonstrated that AAV9 and Anc80 provide limited trans-
duction of spiral ganglion cells and Scarpa’s ganglion cells, consis-
tent with other studies injecting Anc80 via canalostomy.16 To in-
crease the transduction of these bipolar cell types, the
development of a vector with neuron-specific tropism, using a
neuron-specific promoter and/or increasing the viral titer, may
be required.Clinical Development Vol. 17 June 2020 1171
Figure 4. Saccular Hair Cells Are Transduced following the RWM+CF Injection with AAV8, AAV9, and Anc80
(A) Representative images of whole mounts of the saccule. Specimens were stained with Myo7a (red) for labeling and imaged for native EGFP (green). Scale bar, 100 mm. (B)
Quantitative comparison of transduction efficiency after AAV injection as indicated. Data are represented as mean ± SEM.
Molecular Therapy: Methods & Clinical DevelopmentThe major disadvantage of AAV is its small packaging cargo (5.0 kb),
because packaging efficiency sharply declines with sequences
exceeding this limit.11,12,24 To circumvent this limitation, a dual
AAV vector system is needed to carry components of larger trans-
genes (>5 kb) that through various mechanisms are reconstituted.
Choosing the right strategy can impact outcome. One approach em-
ploys homologous recombination: two halves of a large transgene in
dual-AAV vectors share an overlapping region of cDNA and recon-
stitute to form a single large gene.25 An alternative strategy is trans-
splicing, whereby there is a splice donor site in one half of the gene
and its splice acceptor site in the other half. After co-infection,
trans-splicing occurs to reconstitute mRNA, which is translated
into the complete protein.26 This approach has been used successfully
to express large genes in muscle and retina.27,28 A hybrid AAV tech-
nique combines homologous recombination and trans-splicing. Alka-
line phosphatase recombinogenic region (AP) or F1 phage recombi-
nogenic region (AK) is included in each half of the divided gene to
increase recombination between the dual AAVs.29 A final approach
uses inteins, which are self-catalytic protein splicing elements that
self-excise to join the remaining protein portions together in a process
termed protein splicing. Inteins have been used to demonstrate pro-
tein trans-splicing in vitro in mouse, pig, and human retinal
organoids.30
Relevant to the ear are experiments by Al-Moyed et al.,14 who
inserted both halves of the 6-kb-long otoferlin cDNA in two distinct
AAV6 vectors and included sequences to enable trans-splicing.261172 Molecular Therapy: Methods & Clinical Development Vol. 17 JuneThey co-injected into the cochlea of Otof/ mice through the
RWM at post-natal day 6 (P6) and P7. Akil et al.,13 in comparison,
engineered dual AAV2-quadY-F-CMV carrying half-coding se-
quences of Otof and injected Otof/ mice via the RWM on P2,
P17, or P30. Both groups demonstrated efficient trans-splicing in
the context of a dual-vector approach for inner ear gene therapy.
Importantly, while co-transduction is a minimum requirement,
several other processes need to occur for OTOF protein expression
to be realized, including concatemer formation to permit correct
trans-splicing.31 Our results establish the extent to which co-trans-
duction may be rate limiting and demonstrate that for IHCs, AAV2
and AAV9 offer close to 100% transduction efficiency using a sin-
gle-vector approach (Figure 1). A dual AAV2 system is equally robust
(Figure 6). OHC co-transduction is less efficient, likely due to the fact
that transduction with single vectors fails to reach 100%.
Importantly, our data indicate that co-transduction is not influenced
by cooperation between the two vectors or by preferential selection of
the hair cells (Figure 6; Figure S2), which is relevant because dual-vec-
tor transduction is believed to be inferior to single-vector transduc-
tion based on ocular and retinal studies.29 For example, the retinal
transduction efficiency of dual-AAV8 hybrid vectors was only 6%
and 40% of the transduction rate with a single-AAV8 vector in
mice and pigs.29 We observed a similar trend with dual-AAV9-9/
AAV9-EGFP expression, which was reduced while AAV9-mCherry
was maintained, but for AAV2-2 and AAV2-9, co-transduction rates
were similar to single-vector transduction rates. These results suggest2020
(legend on next page)
www.moleculartherapy.org
Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020 1173
Molecular Therapy: Methods & Clinical Developmentthat specific combinations of dual vectors are likely to be important,
an encouraging observation in view of retinal data that have led to
substantial efforts to define compounds that enhance poor dual-
AAV transduction efficiency in the eye.29,31,32 One limitation of
this study is that although we focused on co-transduction following
dual-AAV delivery, we did not assess transgene expression levels
following intermolecular concatamerization. Further studies are
needed to address this question.
In conclusion, we have demonstrated excellent IHCs and OHCs
transduction efficiency with AAV2 in adult mice following RWM+CF
injection. Dual-vector co-transduction of AAV2-2 is equally robust
and efficient. We therefore recommend AAV2 as a serotype to deliver
small and large transgenes into IHCs and OHCs. Further studies are
needed to evaluate the relevance of AAV2 in other species and human
translation, as well the impact of the route of administration and
mouse strain on these observations compared with those in prior
studies. These results should help to guide studies using this vector
and injection method to treat mature murine models of human
deafness.MATERIALS AND METHODS
Ethics Approvals
All experiments were approved by the University of Iowa Institutional
Biosafety Committee (IBC; rDNA Committee; RDNA Approval
Notice #100024) and the University of Iowa Institutional Animal
Care and Use Committee (IACUC; Protocol #06061787), and were
performed in accordance with the NIH Guide for the Care and Use
of Laboratory Animals.Virus Production
AAV1, AAV2, AAV8, AAV9, and Anc80 with a CMV-driven EGFP
transgene andWPRE cassette were prepared by Gene Transfer Vector
Core at theMass Eye and Ear (https://www.vdb-lab.org/vector-core/).
Droplet digital PCR (Bio-Rad, Hercules, CA, USA) was used for titra-
tion of all AAV preparations with primer sets for the transgene
cassette according to the protocol published by Sanmiguel et al.33
Viral titers were AAV1-EGFP at 3.75  1012 GC/mL, AAV2-EGFP
at 3.68  1012 GC/mL, AAV8-EGFP at 4.94  1012 GC/mL,
AAV9-EGFP at 1.20  1013 GC/mL, and Anc80-EGFP at 5.5 
1012 GC/mL. For the dual-injection study, AAV2 and AAV9 carrying
a mCherry-reporter gene and WPRE cassette were provided by the
same laboratory. Viral titers were AAV2-mCherry at 2.15  1012
GC/mL and AAV9-mCherry at 2.48  1012 GC/mL. To compare
transduction efficiency and safety at equal dose, we diluted AAV8,
AAV9, and Anc80 with the final formulation buffer (FFB) to a con-
centration of 3.75–3.80 1012 GC/mL for the single-vector injection.
FFB is composed of 1X PBS + 35 mM NaCl + 0.001% PF-68. For the
dual-vector experiment, vectors were mixed together with pipettingFigure 5. Transduction in the Stria Vascularis, Spiral Ganglion Cells, Saccules,
Midmodiolar cross-sectional images were immunostained with anti-GFP (green), anti-
regions marked with white dotted squares in the cochlea show IHC, OHC, and SCs. A
1174 Molecular Therapy: Methods & Clinical Development Vol. 17 Junewithout FFB. The final concentrations were as follows: AAV2-
EGFP at 1.84  1012 GC/mL, AAV2-mCherry at 1.07  1012 GC/
mL, AAV9-EGFP at 1.2  1012 GC/mL, and AAV9-mCherry at
1.24  1012 GC/mL. Vector aliquots were stored at 80C and
thawed before use.Animal Surgery
RWM+CF injection was carried out as described previously.4 C3H/
FeJ mice at 4 weeks of age were anesthetized with an intraperitoneal
injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Body
temperature was maintained with a heating pad during the surgical
procedure. The left post-auricular region was shaved and cleaned.
A post-auricular incision was made to access the temporal bone.
The facial nerve was identified deep along the wall of the external
auditory canal. After exposing the facial nerve and the sternocleido-
mastoid muscle, a portion of the muscle was divided to expose the co-
chlea bulla ventral to the facial nerve. The posterior semicircular canal
(PSCC) was exposed dorsal to the cochlea bulla. A 0.5- to 1.0-mm-
diameter otologic drill was used to make a small hole in the cochlea
bulla, which was then widened sufficiently with forceps to visualize
the stapedial artery and the RWM. A hole was also drilled in the
PSCC with a 0.5-mm-diameter diamond drill; slow egress of peri-
lymph confirmed a patent canalostomy. After waiting 5–10 min for
perilymph egress to abate, 1.0 mL AAV vectors with 2.5% fast green
dye (Sigma-Aldrich, St. Louis, MO, USA) was loaded into a borosili-
cate glass pipette (Harvard Apparatus, Hollison, MA, USA). For the
dual-injection study, 0.5 mL of each AAV vector was loaded into
the same glass pipette, creating 1:1 mixture of the dual vectors. Pi-
pettes were manually controlled with a micropipette manipulator.
The RWM was punctured gently in the center, and AAV was micro-
injected into the scala tympani for 5 min (30–40 nL per injection).
Successful injections were confirmed by visualizing the efflux of green
fluid from the PSCC canalostomy. After pulling out the pipette, the
RWM niche was sealed quickly with a small plug of muscle to avoid
leakage. The bony defect of the bulla and canal was sealed with small
plugs of muscles and tissue adhesive. Total surgical time ranged from
30 to 50min.When all procedures were finished, mice were placed on
a heating pad for recovery with bedding. Pain was controlled with bu-
prenorphine (0.05 mg/kg) and flunixin meglumine (2.5 mg/kg) for
3 days. Recovery was closely monitored daily for at least 5 days
post-operatively.Auditory Testing
ABRs were recorded as described previously.4,34 All mice were anes-
thetized with an intra-peritoneal injection of ketamine (100 mg/kg)
and xylazine (10 mg/kg). All recordings were conducted from both
ears of all animals on a heating pad, and electrodes were placed sub-
cutaneously in the vertex, underneath the left or right ear. Clicks were
square pulses 100 ms in duration, and tone bursts were 3 ms in lengthand Scarpa’s Ganglion Cells Is Vector Dependent
TuJ1 (red), phalloidin (magenta), and DAPI (blue). High-magnification views of the
rrowheads indicate transduced cells in SV.
2020
Figure 6. Dual-AAV2 and AAV2 Vectors Transduce Adult Murine IHCs and OHCs
(A) Cochleae harvested 2 weeks after co-administrating the combination of AAV2-2 via a RWM+CF approach in 4-week-old C3H/FeJ mice. Representative low-magnifi-
cation images of whole-mount apical turns and high-magnification images of regions along the cochlea duct 0.8–1.2mm (apex), 2.2–2.6mm (middle), and 3.8–4.2mm (base)
from the apical tip. Cochleae were stained with Myo7a (blue) for labeling and imaged for native EGFP (green) and mCherry (red). Scale bar, 100 mm. (B and C) Quantitative
comparison of IHC (B) and OHC (C) transduction efficiency assessed in 400-mm segments across different regions of the cochlea (apex, middle, and base) following the
RWM+CF injection of the combinations of AAV2-2. (D) Click and tone-burst ABRs show auditory thresholds in injected (solid line) and non-injected (dashed line) ears were
comparable following delivery of the combination of AAV2-2. Data are represented as mean ± SEM. Statistical analysis by Student’s t test. *p < 0.05.
www.moleculartherapy.orgat distinct 8-, 16-, 24-, and 32-kHz frequencies. ABRs were measured
with BioSigRZ (Tucker-Davis Technologies, Alachua, FL, USA) for
both clicks and tone bursts, adjusting the stimulus levels in 5-dB in-
crements between 10 and 90 dB sound pressure levels (SPLs) in both
ears. Electrical signals were averaged over 512 repetitions. ABR
threshold was defined as the lowest sound level at which a reproduc-
ible waveform could be observed. ABRs were measured 2 weeks after
the injection. Responses from the right ear, which did not undergo
surgery, were used as controls.
Immunohistochemistry
Bilateral inner ears were harvested 2 weeks after animals were sacri-
ficed by CO2 inhalation. Temporal bones were locally perfused and
fixed in 4% paraformaldehyde for 2 h at room temperature, rinsed
in PBS, and stored at 4C in preparation for immunohistochemistry.
Specimens were visualized with a dissectionmicroscope and dissected
for whole-mount analysis. In all of the cochlear and vestibular whole
mounts, EGFP or mCherry was detected by its native fluorescence.
Following infiltration using 0.3% Triton X-100 and blocking with
5% normal goat serum for 30 min at room temperature, tissues
were incubated with rabbit polyclonal Myosin-VIIA antibody (#25–
6790; Proteus Biosciences, Ramona, CA, USA) diluted 1:200 in PBS
for 1 h. Subsequently, for the single-vector study, fluorescence-labeled
goat anti-rabbit IgG Alexa Fluor 568 (#A-11036; Thermo Fisher Sci-
entific, Rockford, IL, USA) in 1:500 dilution was used as a secondary
antibody for 30 min. For the dual-vector study, goat anti-rabbit IgG
Alexa Flour 405 (#A-31556; Thermo Fisher Scientific) in 1:500 dilu-
tion was used as a secondary antibody for 2 h. For cryo-sectioning,Moleculatemporal bones were decalcified in 0.12 M EDTA for 2 days, cryopro-
tected in 15% and 30% sucrose, and embedded in OCT solution.
Fourteen-micrometer-thick sections were prepared, and immunohis-
tochemistry was performed. Following infiltration using 0.3% Triton
X-100 and blocking with 5% normal goat serum for 30 min, the spec-
imens were incubated in the following primary antibodies diluted in
PBS: (1) mouse monoclonal anti-Green Fluorescent Protein antibody
(MAB3580; Millipore Sigma, Burlington, MA, USA) at 1:200; and (2)
rabbit polyclonal anti-Tubulin b-3 Antibody (#802001; BioLegend,
San Diego, CA, USA) at 1:1,000 overnight at 4C. We used goat
anti-mouse IgG Alexa Fluor 488 (#A-11001; Thermo Fisher Scienti-
fic) and goat anti-rabbit IgG Alexa Fluor 568 (#A-11036; Thermo
Fisher Scientific) diluted at 1:500 in PBS as secondary antibodies
for 30 min. Filamentous actin was labeled by a 30-min incubation
of phalloidin conjugated to Alexa Fluor 647 (#A22287; Thermo Fisher
Scientific) in 1:100 dilution. Specimens were mounted with ProLong
Diamond Antifade Mountant with DAPI (#P36962; Thermo Fisher
Scientific) for the single-vector study and ProLong Diamond Antifade
Mountant (#P36961; Thermo Fisher Scientific) for the dual-vector
study, and observed with a Leica TCS SP8 confocal microscope (Leica
Microsystems, Bannockburn, IL, USA).
Cell Counts and Transduction Efficiency Analysis
Cell counts and transduction efficiency analysis were performed as
described previously.4,35 z stack images of whole mounts were
collected at 10–20 on a Leica SP8 confocal microscope. Each turn
of the cochlea was analyzed: 0.8–1.2 mm (apex), 2.2–2.6 mm (mid-
dle), and 3.8–4.2 mm (base) of the total length from the apical tip.r Therapy: Methods & Clinical Development Vol. 17 June 2020 1175
Molecular Therapy: Methods & Clinical DevelopmentThe corresponding approximate frequencies are 8, 16, and 32 kHz,
respectively.36 Maximum intensity projections of z stacks were gener-
ated for each field of view, and images were prepared using LAS X
(Leica Microsystems) to meet equal conditions. IHCs with positive
EGFP and overlapping Myo7a were counted per 400-mm cochlear
sections for each turn in each specimen with ImageJ Cell Counter
(NIH Image). The total number of HCs and GFP-positive HCs
were summed and converted to a percentage.
Statistical Analysis
Sample sizes are noted in the figure legends. Cell counting and ABR
data are presented as mean ± SEM. Statistical analysis was performed
using Prism 8 software package (GraphPad, San Diego, CA, USA).
Two groups were compared using unpaired two-tailed Student’s t
test. For comparisons of more than two groups, one-way ANOVA
was performed and followed by post hoc test with Bonferroni correc-
tion of pairwise group differences. p <0.05 was considered statistically
significant.
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